During the corresponding time, Atara Biotherapeutics Inc saw a revenue deteriorated by -96.44 % year on year, sequentially revenue grew by 10.53 %. While revenue at the Atara Biotherapeutics Inc 's corporate clients
Atara Biotherapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers including the Veterans Administration, Department of Defense (including military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and Public Health Service (PHS). Eligible purchasers also include hospitals serving a disproportionate share of financially needy patients, community health clinics, and other entities receiving health services grants from the PHS. Operating within the U.S. market, the company is affected by federal healthcare programs such as the Medicaid Drug Rebate Program and Medicare Part D. Its pricing and coverage are influenced by legislative and regulatory frameworks, including the Affordable Care Act and subsequent amendments.
Atara Biotherapeutics Announces Second Quarter 2025 Financial Results and Noteworthy Operational Progress in T-Cell Immunotherapy Development Thousand Oaks, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), renowned as a pioneer in T-cell immunotherapy, continues to spearhead transformative therapies that offer hope to patients battling cancer and autoimmune diseases. In its latest corporate disclosure, the company has revealed its financial results for the second quarter of 2025 as well as significant strides in its operational endeavors, providing a robust update on its drug development pipeline.Atara employs a groundbreaking approach by leveraging its unique allogeneic Epstein-Barr virus (EBV) T-cell...
Advancing Innovation: Atara Biotherapeutics Resubmits BLA for Groundbreaking T-Cell Therapy, Amidst Impressive Growth Atara Biotherapeutics, Inc. (Nasdaq: ATRA) is making waves in the biotech industry with an impressive blend of scientific innovation and business acumen. The Thousand Oaks-based leader in T-cell immunotherapy recently announced significant progress in its mission to provide transformative therapies for patients suffering from cancer and autoimmune diseases. By resubmitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO or tab-cel), Atara underscores its commitment to delivering cutting-edge solutions in the medical field, settin...
In a landscape defined by rapid advancements in immunotherapy, Atara Biotherapeutics (Nasdaq: ATRA) stands out as a promising leader in T-cell immunotherapy, particularly through its pioneering allogeneic Epstein-Barr virus (EBV) T-cell platform. However, recent announcements regarding clinical holds on key investigational new drug (IND) applications have raised questions about the company’s immediate future and the broader implications for its innovative therapies aimed at treating cancer and autoimmune diseases. Clinical Hold on Key Programs On a significant note, Atara Biotherapeutics confirmed that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its active IND applications, i...
Atara Biotherapeutics, Inc. a prominent biotechnology company specializing in T-cell immunotherapy, has recently announced its participation in the upcoming Stifel 2024 Healthcare Conference. The company s President and Chief Executive Officer, Dr. Cokey Nguyen, is slated to engage in a fireside chat during this significant event, scheduled for November 18, 2024, at 6:10 a.m. PST / 9:10 a.m. EST. This involvement not only highlights Atara s commitment to transparency and investor engagement but also serves as an important platform to discuss its innovative developments in the realm of cell therapy.Atara Biotherapeutics is recognized for its pioneering allogeneic Epstein-Barr virus (EBV) T-cell platform, a te...
Atara Biotherapeutics Showcases Promising Preclinical Data for ATA3219 CAR T Therapy for Autoimmune Diseases at ISCT 2024 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneering entity in T-cell immunotherapy, has released preclinical data that accentuates the potential of its latest therapy candidate, ATA3219, at the International Society for Cell and Gene Therapy (ISCT) 2024 Annual Meeting. Focused on tackling B-cell driven autoimmune disorders, ATA3219 is an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy grounded in Atara’s innovative allogeneic Epstein-Barr virus (EBV) T-cell platform.This announcement is particularly significant as it underscores the therapeutic potential of ATA...
Atara Biotherapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers including the Veterans Administration, Department of Defense (including military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and Public Health Service (PHS). Eligible purchasers also include hospitals serving a disproportionate share of financially needy patients, community health clinics, and other entities receiving health services grants from the PHS. Operating within the U.S. market, the company is affected by federal healthcare programs such as the Medicaid Drug Rebate Program and Medicare Part D. Its pricing and coverage are influenced by legislative and regulatory frameworks, including the Affordable Care Act and subsequent amendments.
Sources:
Atara Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Atara Biotherapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Atara Biotherapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
